Company intelligence / Profile preview

Trefoil Therapeutics

San Diego, California, United Statestrefoiltherapeutics.com ↗

Ownership: Private
Employees: ~11
Development stage: Phase 2

Overview

Trefoil Therapeutics’ lead candidate TTHX1114, an engineered variant of FGF1, has shown in Phase 2 clinical trials to improve the rate of visual recovery after Descemet Stripping Only (DSO) surgery in patients with corneal endothelial dystrophies. The company also completed a Phase 1 safety study for a topical formulation targeting epithelial disorders in April 2023. Both formulations aim to stimulate regeneration and protection of corneal cells, addressing significant unmet needs in ophthalmology.

Therapeutic areas: Ophthalmology
Modalities: Engineered proteins (specifically engineered FGF1/eFGF1)Biologics
Industry: Biotech

Drug pipeline

1 asset

TTHX1114

Partnerships

Technology licensed from Florida State University; no major pharma partnerships disclosed.

Beyond the preview

Go deeper on Trefoil Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trefoil Therapeutics.

Explore the full profile